Centene Corporation reported strong Q2 earnings with adjusted diluted EPS of $2.51 and raised its 2026 adjusted EPS guidance to over $4.80, signaling higher expected full-year profits. Improved cost management enhanced profitability, with the Marketplace pretax margin outlook increased to 4.5-5% and a Commercial Health Benefit Ratio of 79.2%. Morgan Stanley responded by raising Centene's price target from $57 to $66, reflecting nearly 6% upside potential and growing confidence in the company's financial trajectory. CEO Sarah M. London highlighted these results as key milestones toward restoring profitability and delivering better health outcomes efficiently.
Centene reported a net income of $1.09 billion in Q2 2026, reversing a $253 million loss from the previous year, driven by better control of rising medical costs and a lower health benefits ratio of 89.6%. Despite a sharp drop in Obamacare marketplac...
Canada Nickel Company has extended the repayment date of its $32 million loan from Auramet International from August 9, 2026, to November 9, 2026. The extension includes a fee of $856,288 and the issuance of 5.5 million share purchase warrants to Aur...
Centene Corporation announced the retirement of Kenneth A. Burdick from its Board of Directors, effective July 28, 2026, and the appointment of Paul J. Diaz to the Board on the same date. Burdick, who joined in 2022, brought extensive healthcare lead...
